Person who experienced the adverse event (patient)
| Event ID | CASE | I F COD | FOLL SEQ | IMAGE | EVENT DT | MFR DT | FDA DT | REPT COD | MFR NUM | MFR SNDR | AGE | AGE COD | GNDR COD | E SUB | WT | WT COD | REPT DT | OCCP COD | DEATH DT | TO MFR | CONFID | REPORTER COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5120031 | 6127199 | F | 2 | 5120031-6 | 20060816 | 20060919 | 20060929 | EXP | 2006100615 | PFIZER INC | 45 | YR | M | N | 84.1 | KG | 20060928 | OT | UNITED KINGDOM |
Drug(s) used by person
| Event ID | DRUG SEQ | ROLE COD | DRUGNAME | VAL VBM | ROUTE | DOSE VBM | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5120031 | 1007726845 | PS | SUTENT | 1 | ORAL | 50 MG (50 MG, CYCLIC QD: 4 WEEKS ON, 2 WEEKS OFF), ORAL | Y | D | 21968 | ||
| 5120031 | 1007745790 | C | ATENOLOL | 1 |
Indications of drugs used
| Event ID | DRUG SEQ | INDI PT |
|---|---|---|
| 5120031 | 1007726845 | RENAL CELL CARCINOMA STAGE UNSPECIFIED |
Outcome of event
| Event ID | OUTC COD |
|---|---|
| 5120031 | HO |
| 5120031 | LT |
Reactions reported
| Event ID | PT |
|---|---|
| 5120031 | ASPARTATE AMINOTRANSFERASE INCREASED |
| 5120031 | BLOOD ALBUMIN DECREASED |
| 5120031 | BLOOD ALKALINE PHOSPHATASE INCREASED |
| 5120031 | BLOOD BILIRUBIN INCREASED |
| 5120031 | BLOOD CALCIUM DECREASED |
| 5120031 | FASCIITIS |
| 5120031 | LOWER GASTROINTESTINAL HAEMORRHAGE |
| 5120031 | LYMPHOCYTE COUNT DECREASED |
| 5120031 | PERIANAL ABSCESS |
| 5120031 | PURULENT DISCHARGE |
| 5120031 | SUBCUTANEOUS ABSCESS |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | RPSR COD |
|---|---|
| 5120031 | FGN |
| 5120031 | HP |
| 5120031 | SDY |
Therapies reported
| Event ID | DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|
| 5120031 | 1007726845 | 20060803 | 20060816 |